IP Library › Granted Patent US 10,716,793
Granted Patent B2
US 10,716,793 · App. 16/778,662 · Granted Jul 21, 2020

Treprostinil administration by inhalation

Inventors: Horst Olschewski (Graz, AT); Robert Roscigno (Chapel Hill, NC); Lewis J. Rubin (LaJolla, CA); Thomas Schmehl (Giessen, DE); Werner Seeger (Giessen, DE); Carl Sterritt (Weybridge, GB); Robert Voswinckel (Giessen, DE)
Assignee: United Therapeutics Corporation
A61K31/557A61K9/008A61K9/0078A61K31/192
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,716,793
App. No.
16/778,662
Granted
Jul 21, 2020
Kind
B2
Abstract

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Claims (8)

1. A method of treating pulmonary hypertension comprising administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising treprostinil or a pharmaceutically acceptable salt thereof with an inhalation device, wherein the therapeutically effective single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof delivered in 1 to 3 breaths.

2. The method of claim 1 , wherein the inhalation device is a soft mist inhaler.

3. The method of claim 1 , wherein the inhalation device is a pulsed ultrasonic nebulizer.

4. The method of claim 1 , wherein the inhalation device is a dry powder inhaler.

5. The method of claim 1 , wherein the inhalation device is a pressurized metered dose inhaler.

6. The method of claim 4 , wherein the formulation is a powder.

7. The method of claim 6 , wherein the powder comprises particles less than 5 micrometers in diameter.

8. The method of claim 1 , wherein the formulation contains no metacresol.

Continuity (7)
Continuation 16536954 · Aug 9, 2019
Continuation 15011999 · Feb 1, 2016
Division 13469854 · May 11, 2012
Division 12591200 · Nov 12, 2009
Continuation 11748205 · May 14, 2007
Provisional Application 60800016 · May 15, 2006
Related Publication 20200171044A1 · Jun 4, 2020
Cited By (4)
US 12,390,475 US 12,697,315 US 12,734,143 US 12,740,954